目的 探討桂枝茯苓片聯(lián)合頭孢曲松治療慢性盆腔炎的臨床療效。方法 選取2020年2月—2023年1月陜西省中醫(yī)醫(yī)院收治的94例慢性盆腔炎患者，按隨機(jī)數(shù)字表法將所有患者分為對照組和治療組，每組各47例。所有患者于月經(jīng)結(jié)束3 d后給藥。對照組靜脈滴注注射用頭孢曲松鈉，將2.0 g充分溶解于250 mL生理鹽水，1次/d。治療組在對照組基礎(chǔ)上口服桂枝茯苓片，3片/次，3次/d。兩組療程均為14 d。觀察兩組的臨床療效，比較治療前后兩組癥狀、體征、輔助檢查積分及盆腔包塊最大徑、癥狀自評量表（SCL-90）評分、世界衛(wèi)生組織生活質(zhì)量測定簡表（WHOQOL-BREF）評分和紅細(xì)胞沉降率（ESR）、中性粒細(xì)胞與淋巴細(xì)胞比值（NLR）、C反應(yīng)蛋白（CRP）水平。結(jié)果 治療后，治療組總有效率為95.74%，顯著高于對照組的82.98%（P＜0.05）。治療后，兩組患者主癥、次癥、盆腔局部體征、輔助檢查積分及其總積分均顯著降低（P＜0.05）；且均以治療組降低更顯著（P＜0.05）。治療后，兩組盆腔包塊最大徑和SCL-90評分均顯著降低，而WHOQOL-BREF評分均顯著增加（P＜0.05）；且以上評分均以治療組改善更顯著（P＜0.05）。治療后，兩組ESR、NLR、CRP水平均顯著下降（P＜0.05）；治療后，治療組ESR、NLR、CRP水平均顯著低于對照組（P＜0.05）。結(jié)論 桂枝茯苓片聯(lián)合頭孢曲松治療慢性盆腔炎的整體效果確切，患者可有效獲得癥狀體征的明顯減輕，促進(jìn)盆腔包塊縮小及身心健康、生活質(zhì)量的改善，調(diào)節(jié)機(jī)體血液流變學(xué)及炎癥狀態(tài)，值得臨床推廣應(yīng)用。

Objective To explore the clinical efficacy of Guizhi Fuling Tablets combined with ceftriaxone in treatment of chronic pelvic inflammatory disease. Methods 94 Patients with chronic pelvic inflammatory disease treated in Shaanxi Provincial Hospital of Traditional Chinese Medicine from February 2020 to January 2023 were selected and divided into control group and treatment group according to random number table method, with 47 cases in each group. All patients were given the drug 3 d after the end of menstruation. Patients in the control group were iv administered with Ceftriaxone Sodium for injection, 2.0 g was fully dissolve in 250 mL normal saline, once daily. Patients in the treatment group were po administered with Guizhi Fuling Tablets on the basis of the control group, 3 tablets/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacy was evaluated, symptoms, signs, auxiliary examination scores, maximum diameter of pelvic masses, Symptom Checklist 90 (SCL-90) scores, World Health Organization Quality of Life Brief (WHO QOL BREF) scores, erythrocyte sedimentation rate (ESR), neutrophil to lymphocyte ratio (NLR), and C-reactive protein (CRP) levels between the two groups before and after treatment were compared. Results After treatment, the total effective rate of treatment group was 95.74%, which was significantly higher than that of control group (82.98%) (P< 0.05). After treatment, the main disease, secondary disease, local pelvic signs, auxiliary examination scores and total scores were significantly decreased in both groups (P < 0.05). The decrease was more significant in the treatment group (P < 0.05). After treatment, the maximum diameter of pelvic mass and SCL-90 score were significantly decreased, while WHOQOL-BREF score was significantly increased in both groups (P < 0.05). The improvement was more significant in the treatment group (P < 0.05). After treatment, the levels of ESR, NLR and CRP in both groups were significantly decreased (P < 0.05). After treatment, the levels of ESR, NLR and CRP in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Guizhi Fuling Tablets combined with ceftriaxone has a definite overall effect in treatment of chronic pelvic inflammation disease, and patients can effectively obtain significant reduction of symptoms and signs, promote the shrinkage of pelvic mass, improve physical and mental health, quality of life, regulate the hemorheology and inflammation state, which is worthy of clinical promotion and application.

R984